NeOnc Technologies CEO Amir Heshmatpour has purchased over $500,000 in company stock on the open market, bringing his total investment to nearly $1 million in the past year. The buying signals strong insider confidence ahead of an expected interim data release for the company's NEO100 brain cancer therapy later in 2026.
NeOnc Technologies Holdings Inc. (Nasdaq: NTHI) Chief Executive Officer Amir Heshmatpour purchased more than $500,000 of company stock in recent weeks, according to regulatory filings, increasing his personal stake ahead of key clinical trial results.
“My continued open-market purchases reflect my conviction not only in our upcoming catalysts, but in the long-term potential of our platform,” Heshmatpour, who is also the company’s chairman and president, said in a May 5 statement.
The recent buying brings Heshmatpour’s total investment to nearly $1 million in personal capital over the past year. A Form 4 filed with the U.S. Securities and Exchange Commission on May 4 showed a purchase of 10,000 shares at a price of $4.1592. All purchases were disclosed as being made with personal funds in the open market.
The accelerated insider buying comes as NeOnc prepares for an interim analysis of its Phase 2a study of NEO100, a therapy for recurrent IDH1-mutant high-grade glioma. The trial is fully enrolled, and the company expects to release the interim data later in 2026. NeOnc also recently completed a Phase 1 dose escalation for another candidate, NEO212, and established a recommended dose for Phase 2 trials.
Unlike the recent insider selling seen at other clinical-stage biotechs like MapLight Therapeutics (MPLT), where an executive sold shares under a pre-scheduled 10b5-1 plan, Heshmatpour’s discretionary purchases suggest a direct vote of confidence in NeOnc’s near-term prospects. Shares of NeOnc closed at $4.14 on Monday, trading significantly below their 200-day moving average of $8.21.
The consistent insider buying provides a strong signal of management’s alignment with shareholders as the company approaches a pivotal data readout for its lead brain cancer candidate. Investors will be closely watching for the interim NEO100 Phase 2a analysis later this year, which will be the next major event for the stock.
This article is for informational purposes only and does not constitute investment advice.
